Nocrav

Nocrav is an oral smoking cessation medication marketed by Lyf Healthcare in India. It contains varenicline (inferred from its 1mg dosage and mechanism of action), which acts as a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptors in the brain. By binding to these receptors, Nocrav reduces the urge to smoke and alleviates withdrawal symptoms associated with nicotine cessation. It is typically administered as a 1mg tablet over a 12-to-24-week treatment course, often in conjunction with counseling and social support. As a branded generic, it provides a therapeutic alternative to the innovator drug Chantix.

Brand names

Nocrav